

Ore Holdings Inc. Announces Approval of License Assignment Agreement for Certain Intellectual Properties

Wellesley, Mass., January 6, 2012. Ore Holdings Inc. (“Ore”)(ticker symbol: ORXE) today announced the approval of a license assignment agreement, whereby Ore granted to p-Value Capital Management, LLC (“p-Value”), Ore’s rights to certain therapeutic products, including its ORE1001 and Irindalone compounds. The agreement provides for certain payments to Ore should p-Value be able to further develop and monetize the value of these products.

As previously reported, Ore has suspended its SEC registration and no longer provides financial or other information through SEC filings. Ore intends to continue to provide quarterly and annual financial information by posting such information on its web site, www.orepharma.com.

To ensure the preservation of the Company’s net operating loss our Certificate of Incorporation limits the ability of stockholders from acquiring more than five percent of our outstanding stock.

Ore Holdings Overview:

Ore Holdings Inc. is currently focused on monetizing its pharmaceutical assets.

Source: Ore Holdings Inc.

Terry Gibson - President, CEO & CFO (408) 399-6490